Single-source drug submissions under review (English, CSV)
Single-source drug submissions under review: English CSV file you can open as a table, filter, chart and export up to 10,000 rows. From Government of Ontario, updated Apr 2026.
- Format
- CSV
- Access
- Table on demand (prepared when opened)
- Publisher-reported update
- 2026-04-17
Information on the status of manufacturers' drug submissions that allows industry stakeholders and the public to track the status of drug submissions through the various stages of the review cycle.
Data overview
- Formats
- CSV
- File languages
- English
- Available actions
- Explore table (prepared automatically) · Access original file
Sample rows
The first 10 rows, as CanQuery read them from the start of the publisher's file on 2026-11-14.
| Brand Name | Generic Name | Strength and Format | Manufacturer | Indication | Date submission was deemed complete | Review Status |
|---|---|---|---|---|---|---|
| Vyloy | zolbetuximab | 100 mg vial | Astellas Pharma Canada Inc. | In combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of patients with locally advanced unresectable or metastatic human epidermal grow… | 2025-06-19 | Negotiation |
| Enhertu | trastuzumab deruxtecan | 100 mg/vial | AstraZeneca Canada Inc. | Monotherapy for the treatment of HER2-positive advanced gastric or gastroesophageal junction adenocarcinomas who have received a prior trastuzumab-based regimen | 2025-04-28 | Negotiation concluded |
| Welireg | belzutifan | 40 mg tablet | Merck Canada | For the treatment of adult patients with advanced renal cell carcinoma (RCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial g… | 2025-04-08 | Under review (CDA-AMC) |
| Welireg | belzutifan | 40 mg tablet | Merck Canada | For the treatment of adult patients with advanced renal cell carcinoma (RCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial g… | 2025-04-08 | Under review (CDA-AMC) |
| Winrevair | sotatercept | 1x 45 mg kit, 1 x 60 mg kit, 2 x 45 mg kit, 2 x 60 mg kit, 45 mg vial, 60 mg vial | Merck Canada | Treatment of adults with pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) | 2025-03-10 | Negotiation |
| Darzalex SC | daratumumab | 120 mg/mL solution | Johnson & Johnson | Indicated in combination with bortezomib, lenalidomide, and dexamethasone, followed by maintenance treatment in combination with lenalidomide, for the treatment of adult patients with newly diagnosed… | 2025-02-27 | Under review (CDA-AMC) |
| Luxa D | cholecalciferol | 2,000 IU, soft-gel capsule | Orimed Pharma Inc. | For the treatment and prevention of vitamin D deficiency | 2025-02-18 | Review completed (CED) |
| Imdelltra | tarlatamab | 1 mg/vial, 10 mg/vial | Amgen Canada Inc. | For the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after at least two prior lines of therapy including platinum-based chemotherapy | 2025-02-04 | Review completed (CDA-AMC) |
| Bimzelx | bimekizumab | 320 mg/2 mL pre-filled syringe and autoinjector | UCB Canada Inc. | For the treatment of moderate to severe plaque psoriasis (PsO) in adult patients who are candidates for systemic therapy or phototherapy | 2025-02-04 | Review completed CED) |
| Trecondyv | treosulfan | 5 g/vial | Medexus Inc. | In combination with fludarabine as part of conditioning treatment prior to alloHSCT in adult patients with AML or MDS at increased risk for standard conditioning therapies | 2025-01-22 | Negotiation concluded |